Monoclonal antibody therapy for COVID-19 – Part 3

In Part 3 of this series on monoclonal antibody therapies for COVID-19, our expert panel continues their discussion on concerns about the efficacy and distribution of these treatment options. They respond to the FDA’s recent Emergency Use Authorization (EUA) for monoclonal antibodies.
 
Guest speakers:Azra Behlim, PharmD, MBASenior DirectorPharmacy Sourcing and Program Services Vizient
Stacy Lauderdale, PharmDSenior DirectorDrug InformationVizient
Steve Rudner, PharmD, MSDirectorPharmacy Network ContractingVizient
 
Moderator:Tomas Villanueva, DO, MBA, FACPE, SFHMAssociate Vice PresidentClinical ResourcesVizient
 
Show Notes:[00:37] Identifying the right patients – best practices[03:10] The access challenge[05:54] Plenty of availability[06:10] COVID vaccination and use of monoclonal antibody therapy[06:37] Post-infusion management
 
Links | Resources:
Press release and information from FDA Click here
Information from FDA on EUA for monoclonal antibody therapy Click here
ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here
[ For more information, contact: ASPRstakeholder@HHS.gov ]
JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here
 
Subscribe Today!
Apple Podcasts
Spotify
Android
Google Podcasts
Stitcher
RSS Feed
 

Monoclonal antibody therapy for COVID-19 – Part 2

Last November, the FDA released an Emergency Use Authorization (EUA) for the use of monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19. Currently, there is some confusion about the availability and access issues to these treatment options.
 
In this episode, part two of a three-part series, we will address questions and concerns about the distribution and availability of these therapies.
 
Guest speakers:Azra Behlim, PharmD, MBASenior DirectorPharmacy Sourcing and Program Services Vizient
 
Steve Rudner, PharmD, MSDirectorPharmacy Network ContractingVizient
 
Moderator:Tomas Villanueva, DO, MBA, FACPE, SFHMAssociate Vice PresidentClinical ResourcesVizient
 
Show Notes:[02:05] Access to the monoclonal antibody therapies[03:51] No lack of supply[05:07] Infusion options[09:59] Misconceptions and challenges around distribution[11:40] Every idea worth exploring
 
Links | Resources:
Press release and information from FDA Click here
Information from FDA on EUA for monoclonal antibody therapy Click here
ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here
[ For more information, contact: ASPRstakeholder@HHS.gov ]
JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here
 
Subscribe Today!
Apple Podcasts
Spotify
Android
Google Podcasts
Stitcher
RSS Feed
 

Monoclonal antibody therapy for COVID-19 – Part 1

COVID-19 vaccines have dominated the headlines. Not garnering the same attention, but just as important, is last November’s US Food and Drug Administration Emergency Use Authorization (EUA) allowing monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19.
 
This episode, beginning a three-part series on this treatment option, will address questions and concerns about the administration of monoclonal antibody therapy.
 
Guest speaker:
Stacy Lauderdale, PharmD
Senior Director
Drug Information
Vizient
 
Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Associate Vice President
Clinical Resources
Vizient
 
Show Notes:
[01:05] Science behind the treatment
[02:09] Evidence is compelling but hypothesis-generating
[03:43] Choosing an option
[04:37] Role of COVID testing
[04:52] Inclusion and exclusion factors
[06:17] Risk of anaphylaxis
[06:54] Social determinants for treatment
[07:44] Patient risk factors
 
Links | Resources:
Press release and information from FDA Click here
Information from FDA on EUA for monoclonal antibody therapy Click here
ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here
[ For more information, contact: ASPRstakeholder@HHS.gov ]
JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here
 
Subscribe Today!
Apple Podcasts
Spotify
Android
Google Podcasts
Stitcher
RSS Feed
 

Advancing team culture: workforce effectiveness during COVID-19 and beyond – Part 3

In this third and final episode of our series on building a team culture, we examine the role of scope of practice, training and fostering a psychologically safe environment to improve and sustain workforce capability.
 
Guest speakers:
Robert Dean, DO, MBA
Senior Vice President
Performance Management
Vizient
 
Katie Davis, RN, MS-HSM
Clinical Workforce Solutions Intelligence Director
Vizient
 
Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Associate Vice President
Clinical Resources
Vizient
 
Show Notes:
[00:20] Scope of practice and team-based care
[05:59] Core competencies
[08:44] Story from Northwestern Memorial Hospital
[09:38] A new timeline
[09:56] Attributes of a team-based culture
[10:51] The role of virtual health
[11:48] Story from Vidant Health
 
Links | Resources:
Vizient playbook: Advancing team culture for workforce effectiveness Click here
“Disruptive and Toxic Behaviors in Healthcare (Holloway, Kusy) Click here
Leading Frontline COVID-19 Teams: Research-Informed Strategies (Kerrisey, Singer—NEJM Catalyst, September 2020) Click here
What Healthcare Workers Need from Leaders in COVID-19 Crisis (Ratanjee, Foy – Gallup, April 2020) Click here
Diversity Still Matters (Dolan, Hunt, Prince, Sancier-Sultan—McKinsey & Company, May 2020) Click here
“Implementing Optimal Team-Based Care to Reduce Clinician Burnout” (National Academy of Medicine discussion paper – September 17, 2018) Click here
“Association Between Provider Engagement, Staff Engagement, and Culture of Safety” (Journal of Healthcare Quality, July/Aug 2020) Click here
Toxic Workplace!: Managing Toxic Personalities and Their Systems of Power (Kusy, Holloway). Book ordering information: Click here
 
Subscribe Today!
Apple Podcasts
Spotify
Android
Google Podcasts
Stitcher
RSS Feed